Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is poised for success due to their innovative cell-free protein synthesis platform and the potential of their ADCs, especially STRO-004 and STRO-006, as promising treatments for solid tumors. With their strong pipeline and ongoing studies on combination therapies, the company is well-positioned to make a significant impact in the field of cancer treatment. The increase in price target and promising results from preclinical studies further support a positive outlook for Sutro Biopharma.

Bears say

Sutro Biopharma is a clinical-stage pharmaceutical company that specializes in the development of next-generation antibody-drug conjugates (ADCs) for solid tumors. While their proprietary platform and dual-payload ADCs have promising preclinical data, the technical challenges of linker chemistry and payload selection remain a concern. Additionally, the company's valuation is based on optimistic assumptions and there are significant risks that could prevent them from reaching their price target.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.